Navigation Links
Novel pathway regulating angiogenesis may fight retinal disease, cancers
Date:5/29/2011

CINCINNATI Scientists identify in the journal Nature a new molecular pathway used to suppress blood vessel branching in the developing retina a finding with potential therapeutic value for fighting diseases of the retina and a variety of cancers.

Researchers report that myeloid cells, blood cells involved in the immune system, use this molecular pathway to guide blood vessel patterning in the retina. Furthermore, in the same study researchers were able to reverse this pathway to accelerate the growth of branching vessels, which could be important to developing new methods for repairing damaged tissues.

"We show in the setting of retina that myeloid cells use this pathway to direct vascular traffic," explained Richard Lang Ph.D., senior investigator on the study and director of the Visual Systems Group in the Division of Ophthalmology at Cincinnati Children's Hospital Medical Center. "We think modulation of this pathway might become a promising therapeutic option.''

The study, to be published online May 29, demonstrates how retinal myeloid cells regulate blood vessel branching in the still-developing retinas of postnatal mice by using the Wnt protein signaling network. The Wnt pathway is known for its role in embryonic and early development as well as in cancer. Although myeloid cells play an important part in the immune system, these cells are also found in many different tumor types and promote tumor progression.

Through a series of experiments in cell cultures and mouse models, researchers determined the new pathway works by myeloid cells utilizing the Wnt pathway to regulate expression of a gene known as Flt1. Flt1 encodes a protein called vascular endothelial growth factor receptor-1 (VEGFR1), which suppresses vascular growth by binding vascular endothelial growth factor (VEGF). The expression of Flt1 can be adjusted so that when ramped up it inhibits VEGF and vascular branching, or when turned down it allows VE
'/>"/>

Contact: Nick Miller
nicholas.miller@cchmc.org
513-803-6035
Cincinnati Children's Hospital Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. GW researchers reveal 18 novel subtype-dependent genetic variants for autism spectrum disorders and identify potential genetic markers for diagnostic screening
2. Novel ash analysis validates volcano no-fly zones
3. Novel therapy improves immune function in teen with rare disease
4. Data suggest liver experts should take care when prescribing novel antiviral HCV drugs
5. Novel method could improve the performance of proteins used therapeutically
6. Synthetic biology: TUM researchers develop novel kind of fluorescent protein
7. Team creates novel vaccine that produces strong immunity against cocaine high
8. Novel compounds show early promise in treatment of Parkinsons, Huntingtons, Alzheimers
9. GEN co-sponsors roundtable discussion on novel bioremediation techniques
10. In the lab, engineers novel liquid provides a solid fix for broken bones
11. Novel services for tropical forest monitoring with satellite
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 16, 2014  Automation is ... this more evident than at international borders. Over ... document scanners have allowed veteran travelers to self ... Passport Control (APC) Kiosks at an increasing number ... globe. According to Maxine ...
(Date:12/11/2014)... 2014  That blood pressure plays a role in human ... the medical term for high blood pressure – was first ... inflatable cuff that,s used in measuring blood pressure was invented ... new about hypertension, its triggers and its effects. In fact, ... and the best ways to treat it. For ...
(Date:12/10/2014)... Forest Baptist Medical Center today announced plans for a ... Funding for this $50 million capital project is part ... launched next summer. The medical education ... R.J. Reynolds Tobacco Company complex, adjacent to 525@vine in ... plans to be ready to welcome medical students in ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... consider giving thanks for the bacteria-busting ability of cranberry ... beverage holds important clues for preventing cavities. , ... D.D.S., Ph.D., at the University of Rochester Medical Center ... juice a powerful weapon against bladder infections also hold ...
... : It makes me sad when an article that should ... webpage of the student's group in the iGEM competition , ... for their bacterial 'camera'. , Using Petri dishes full ... at The University of Texas at Austin and UCSF successfully ...
... College of Medicine and the German Cancer Research Institute ... regions of a cell--a process crucial for the cellular ... metastasis. Their study appears in the November 24 issue ... Singer and Dr Stefan Huettelmaier, the research team focused ...
Cached Biology News:Give thanks for the cranberry, say dental researchers 2Give thanks for the cranberry, say dental researchers 3Student scientists create living bacterial photographs 2Student scientists create living bacterial photographs 3Einstein scientists discover how protein crucial for motion is synthesised at the right place in the cell 2
(Date:12/24/2014)... LOUIS , Dec. 23, 2014 ... today that the waiting period under the Hart-Scott-Rodino ... the acquisition expired on December 22, 2014, thereby ... review requirement for the acquisition of the Company ... U.S. antitrust clearance satisfies another condition to closing ...
(Date:12/22/2014)... 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, ... today announced positive topline safety and tolerability ... of SYN-004, the Company,s investigational oral beta-lactamase ... difficile (C. difficile) infection, antibiotic-associated diarrhea ...
(Date:12/22/2014)... , Dec. 22, 2014  ( www.competitivehealth.com ) ... an online medical bill review and advocacy service, has ... the FREE WellCard Savings discount health services marketplace. ... that was more than they expected to pay. As ... health care costs, WellCard Savings is pleased to offer ...
(Date:12/19/2014)... 19, 2014 Bioject Medical Technologies ... manufacturer of needle-free injection technology, today announced that ... Therapeutics, Inc. (“ITI”) for ITI to use the ... LAMP™ vaccine platform. , In the agreement, ... license to the Biojector®-2000 that triggers based on ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... , , , ALBANY, Ore., ... financial results for the first quarter of fiscal 2010, which ended ... a 5% decrease compared to revenue of $4.9 million in the ... quarter was $1.0 million, compared to operating income of $314,000 for ...
... Md., Aug. 6 GenVec, Inc. (Nasdaq: GNVC ) today ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO ... net loss of $4.8 million ($0.05 per share) for the three months ... ($0.08 per share) in the comparable quarter of 2008. For the six ...
... 6 Novavax, Inc. (Nasdaq: NVAX ) announced ... Chief Financial Officer and treasurer. Mr. Driscoll will report ... , , Previously Mr. Driscoll served as ... Genelabs Technologies, Inc. Prior to his position at Genelabs, ...
Cached Biology Technology:Synthetech Reports First Quarter Fiscal 2010 Results 2Synthetech Reports First Quarter Fiscal 2010 Results 3Synthetech Reports First Quarter Fiscal 2010 Results 4Synthetech Reports First Quarter Fiscal 2010 Results 5Synthetech Reports First Quarter Fiscal 2010 Results 6GenVec Reports Second Quarter 2009 Financial Results 2GenVec Reports Second Quarter 2009 Financial Results 3GenVec Reports Second Quarter 2009 Financial Results 4GenVec Reports Second Quarter 2009 Financial Results 5GenVec Reports Second Quarter 2009 Financial Results 6GenVec Reports Second Quarter 2009 Financial Results 7Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer 2
Anti Autotaxin /ENPP2 , - (Rabbit)...
Mouse polyclonal antibody to TNPO2 - transportin 2 (importin 3, karyopherin beta 2b)...
...
Mouse monoclonal antibody to ALAS2 - aminolevulinate, delta-, synthase 2 (sideroblastic/hypochromic anemia)...
Biology Products: